Literature DB >> 32923880

Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma.

Waleed Kian1, Laila C Roisman1, Iris M Goldstein1, Abed Abo-Quider2, Benzion Samueli3, Nadav Wallach4, Farouq Alguayn5, Walid Shalata1, Dina Levitas1, Olga Belochitski1, Daniel Levin6, Eyal Fenig7, Konstantin Lavrenkov1, Margarita Tokar1, Nir Peled1, Alexander Yakobson1.   

Abstract

Entities:  

Year:  2020        PMID: 32923880      PMCID: PMC7446390          DOI: 10.1200/PO.19.00264

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


× No keyword cloud information.
  15 in total

1.  Clinical utility gene card for: Gorlin syndrome.

Authors:  Lorenzo Lo Muzio; Lorenza Pastorino; Sonja Levanat; Vesna Musani; Mima Situm; Giovanna Bianchi Scarra
Journal:  Eur J Hum Genet       Date:  2011-02-09       Impact factor: 4.246

2.  Medulloblastoma in adults : A retrospective single institution analysis.

Authors:  Indrawati Hadi; Olarn Roengvoraphoj; Maximilian Niyazi; Falk Roeder; Ulrich Schüller; Claus Belka; Silke Birgit Nachbichler
Journal:  Strahlenther Onkol       Date:  2017-11-16       Impact factor: 3.621

3.  Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Authors:  Giles W Robinson; Brent A Orr; Gang Wu; Sridharan Gururangan; Tong Lin; Ibrahim Qaddoumi; Roger J Packer; Stewart Goldman; Michael D Prados; Annick Desjardins; Murali Chintagumpala; Naoko Takebe; Sue C Kaste; Michael Rusch; Sariah J Allen; Arzu Onar-Thomas; Clinton F Stewart; Maryam Fouladi; James M Boyett; Richard J Gilbertson; Tom Curran; David W Ellison; Amar Gajjar
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

4.  SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings.

Authors:  Jeannette Parkes; Marc Hendricks; Peter Ssenyonga; John Mugamba; Elizabeth Molyneux; Antoinette Schouten-van Meeteren; Ibrahim Qaddoumi; Graham Fieggen; Sandra Luna-Fineman; Scott Howard; Dipayan Mitra; Eric Bouffet; Alan Davidson; Simon Bailey
Journal:  Pediatr Blood Cancer       Date:  2014-11-21       Impact factor: 3.167

5.  Vismodegib (erivedge) for advanced Basal cell carcinoma.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-12

Review 6.  Molecular subgroups of medulloblastoma.

Authors:  Paul A Northcott; Adrian M Dubuc; Stefan Pfister; Michael D Taylor
Journal:  Expert Rev Neurother       Date:  2012-07       Impact factor: 4.618

7.  Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.

Authors:  Nataliya Zhukova; Vijay Ramaswamy; Marc Remke; Elke Pfaff; David J H Shih; Dianna C Martin; Pedro Castelo-Branco; Berivan Baskin; Peter N Ray; Eric Bouffet; André O von Bueren; David T W Jones; Paul A Northcott; Marcel Kool; Dominik Sturm; Trevor J Pugh; Scott L Pomeroy; Yoon-Jae Cho; Torsten Pietsch; Marco Gessi; Stefan Rutkowski; Laszlo Bognar; Almos Klekner; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Charles G Eberhart; Michelle Fevre-Montange; Maryam Fouladi; Pim J French; Max Kros; Wieslawa A Grajkowska; Nalin Gupta; William A Weiss; Peter Hauser; Nada Jabado; Anne Jouvet; Shin Jung; Toshihiro Kumabe; Boleslaw Lach; Jeffrey R Leonard; Joshua B Rubin; Linda M Liau; Luca Massimi; Ian F Pollack; Young Shin Ra; Erwin G Van Meir; Karel Zitterbart; Ulrich Schüller; Rebecca M Hill; Janet C Lindsey; Ed C Schwalbe; Simon Bailey; David W Ellison; Cynthia Hawkins; David Malkin; Steven C Clifford; Andrey Korshunov; Stefan Pfister; Michael D Taylor; Uri Tabori
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

8.  COSMIC: somatic cancer genetics at high-resolution.

Authors:  Simon A Forbes; David Beare; Harry Boutselakis; Sally Bamford; Nidhi Bindal; John Tate; Charlotte G Cole; Sari Ward; Elisabeth Dawson; Laura Ponting; Raymund Stefancsik; Bhavana Harsha; Chai Yin Kok; Mingming Jia; Harry Jubb; Zbyslaw Sondka; Sam Thompson; Tisham De; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

9.  Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.

Authors:  Gregorio J Petrirena; Julien Masliah-Planchon; Quentin Sala; Bertrand Pourroy; Didier Frappaz; Emeline Tabouret; Thomas Graillon; Jean-Claude Gentet; Olivier Delattre; Olivier Chinot; Laetitia Padovani
Journal:  Oncotarget       Date:  2018-01-03

10.  Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma.

Authors:  Hiromichi Suzuki; Sachin A Kumar; Shimin Shuai; Ander Diaz-Navarro; Ana Gutierrez-Fernandez; Pasqualino De Antonellis; Florence M G Cavalli; Kyle Juraschka; Hamza Farooq; Ichiyo Shibahara; Maria C Vladoiu; Jiao Zhang; Namal Abeysundara; David Przelicki; Patryk Skowron; Nicole Gauer; Betty Luu; Craig Daniels; Xiaochong Wu; Antoine Forget; Ali Momin; Jun Wang; Weifan Dong; Seung-Ki Kim; Wieslawa A Grajkowska; Anne Jouvet; Michelle Fèvre-Montange; Maria Luisa Garrè; Amulya A Nageswara Rao; Caterina Giannini; Johan M Kros; Pim J French; Nada Jabado; Ho-Keung Ng; Wai Sang Poon; Charles G Eberhart; Ian F Pollack; James M Olson; William A Weiss; Toshihiro Kumabe; Enrique López-Aguilar; Boleslaw Lach; Maura Massimino; Erwin G Van Meir; Joshua B Rubin; Rajeev Vibhakar; Lola B Chambless; Noriyuki Kijima; Almos Klekner; László Bognár; Jennifer A Chan; Claudia C Faria; Jiannis Ragoussis; Stefan M Pfister; Anna Goldenberg; Robert J Wechsler-Reya; Swneke D Bailey; Livia Garzia; A Sorana Morrissy; Marco A Marra; Xi Huang; David Malkin; Olivier Ayrault; Vijay Ramaswamy; Xose S Puente; John A Calarco; Lincoln Stein; Michael D Taylor
Journal:  Nature       Date:  2019-10-09       Impact factor: 49.962

View more
  1 in total

Review 1.  Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?

Authors:  Lidia Gatto; Enrico Franceschi; Alicia Tosoni; Vincenzo Di Nunno; Stefania Bartolini; Alba Ariela Brandes
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.